Abbott Laboratories stock heads into TCT data event with Navitor readout

Abbott Laboratories has a scheduled clinical-data event for Monday, November 2, when researchers are due to present five-year outcomes from the IDE study for Abbott's Navitor TAVI system at TCT 2026. The timing and study context were reported by Market Chameleon.

Navitor data set next week's focus

The Navitor presentation is scheduled for 3:30 p.m. Pacific time during the 38th Transcatheter Cardiovascular Therapeutics symposium in San Diego. The five-year readout gives investors a defined point to assess longer-term clinical outcomes for a transcatheter aortic valve system within Abbott's cardiovascular portfolio.

Cephea trial expands development pipeline

Abbott has also initiated the CROWN-MV pivotal study for its investigational Cephea Mitral Valve System. The global prospective trial is planned to enroll up to 585 patients in the United States, Canada and Europe with symptomatic mitral valve disease who are not candidates for surgery or transcatheter repair.

Cephea is designed as a catheter-based mitral valve replacement delivered through a vein in the leg. Market Chameleon reported that Abbott expects early feasibility outcomes for the third-generation delivery system to be presented during TCT 2026.

Clinical milestones matter for investors

The Monday presentation and the new pivotal study keep Abbott's structural-heart development activity in focus. Navitor is an established program in the company's cardiovascular lineup, while Cephea remains investigational in the United States, making the next clinical updates relevant to the portfolio's longer-term development path.

The real-time quote of Abbott Laboratories stock was 95.13 euros on Lang & Schwarz at 17:00 CET on Sunday, November 1, 2026.

Broader trading conditions can be followed in the S&P 500 market environment.

More news and analyses on Abbott Laboratories stock.